Absci Corp Files 8-K: Corporate Details Updated
Ticker: ABSI · Form: 8-K · Filed: Sep 4, 2024 · CIK: 1672688
| Field | Detail |
|---|---|
| Company | Absci CORP (ABSI) |
| Form Type | 8-K |
| Filed Date | Sep 4, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, filing
TL;DR
Absci Corp filed an 8-K updating its corporate address and details.
AI Summary
On September 4, 2024, Absci Corp filed an 8-K report. The filing indicates that the company is located at 18105 SE Mill Plain Blvd, Vancouver, WA 98683, and its principal executive offices are also at this address. The report confirms Absci Corp's incorporation in Delaware and provides its IRS Employer Identification Number as 85-3383487.
Why It Matters
This filing serves as an official update to Absci Corp's corporate information, including its principal executive offices and other identifying details, which is important for investors and regulatory tracking.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not contain information that inherently increases or decreases risk.
Key Players & Entities
- Absci Corp (company) — Registrant
- 18105 SE Mill Plain Blvd, Vancouver, WA 98683 (location) — Principal executive offices
- September 4, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 85-3383487 (identifier) — IRS Employer Identification No.
FAQ
What is the primary purpose of this 8-K filing for Absci Corp?
The primary purpose of this 8-K filing is to report current information as of September 4, 2024, including details about the registrant, its principal executive offices, and its state of incorporation.
What is Absci Corp's principal executive office address?
Absci Corp's principal executive office is located at 18105 SE Mill Plain Blvd, Vancouver, WA 98683.
In which state is Absci Corp incorporated?
Absci Corp is incorporated in Delaware.
What is Absci Corp's IRS Employer Identification Number?
Absci Corp's IRS Employer Identification Number is 85-3383487.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is September 4, 2024.
Filing Stats: 923 words · 4 min read · ~3 pages · Grade level 16.8 · Accepted 2024-09-04 07:30:43
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share ABSI The Nasdaq Glo
Filing Documents
- absc-20240904.htm (8-K) — 29KB
- 0001628280-24-039225.txt ( ) — 154KB
- absc-20240904.xsd (EX-101.SCH) — 2KB
- absc-20240904_lab.xml (EX-101.LAB) — 22KB
- absc-20240904_pre.xml (EX-101.PRE) — 13KB
- absc-20240904_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. Absci Corporation (the "Company") has successfully completed the first milestone in its AI-driven drug discovery collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target. The Company successfully delivered AI de novo designed antibody sequences to AstraZeneca in fulfillment of the first milestone under the collaboration, first announced in December 2023. Following election by AstraZeneca, the Company and AstraZeneca will advance the antibody sequences into AI-lead optimization. The collaboration combines the Company's Integrated Drug Creation platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K, including the information incorporated by reference herein, contains forward-looking statements. Statements in this Current Report on Form 8-K may include statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "potential," and variations of such words or similar expressions. The Company intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including our ability to advance our collaboration with AstraZeneca into lead optimization and to achieve our goals of bringing a new generation of AI-created therapeutics to patients i